LIfT BioSciences is developing portfolio of immuno-oncology cell therapies builds on innate cancer immunity and Leukocyte Infusion Therapy (LIfT). It is also developing worlds first cell bank of cancer killing Granulocytes (a type of white blood cell), to provide a range of potentially life-saving immuno-oncology cell therapies for different solid tumour types.
LIfT BioSciences was set-up with Prof Zhen Cui of Wake Forest University, a leading pioneer in LIFT, following his discovery of a cancer resistant (SR/CR) mouse that proved to have transferable innate immunity.